Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer
Mené sur 635 patients atteints d'un cancer de la prostate résistant à la castration et de stade métastatique, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du custirsen, un oligonucléotide antisens de seconde génération, à un traitement combinant cabazitaxel et prednisone, après l'échec d'un traitement par docétaxel
Taxane chemotherapy, including docetaxel in the front-line and cabazitaxel in the second-line setting, are mainstays of treatment for metastatic castration-resistant prostate cancer. In the phase 3 AFFINITY trial reported in The Lancet Oncology,1 Tomasz Beer and colleagues investigated whether the addition of custirsen, an antisense oligonucleotide that targets the clusterin chaperone protein, improved overall survival when added to cabazitaxel in patients with metastatic castration-resistant prostate cancer that had progressed after previous docetaxel treatment.
The Lancet Oncology , commentaire, 2016